Press Releases

A comprehensive library of Ipsen media releases for investors and members of the press.

Explore more press releases

Filter

Topics

Period

Filter by

recent search

Showing: 105 of 173 Press Releases

Ipsen appoints Keira Driansky as EVP, President of North America

PARIS, FRANCE, 2 May 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership…


Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.


Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

PARIS, FRANCE; BOSTON, U.S., 22 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The…


Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages…


Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Attachment


Your dedicated contacts